Search Results - "SELIGSON, D"

OS8-64 The use of plastic fasteners for intramedullary nailing by Seligson, D

Get full text

IL04 Femur shaft and supracondylar fractures by Seligson, D

Get full text

Sacituzumab Govitecan-hziy: An Antibody-Drug Conjugate for the Treatment of Refractory, Metastatic, Triple-Negative Breast Cancer by Seligson, John M., Patron, Alexandra M., Berger, Michael J., Harvey, R. Donald, Seligson, Nathan D.

“…Objective: To review the pharmacology, efficacy, and safety of sacituzumab govitecan (-hziy; IMMU-132, Trodelvy) for patients with metastatic triple-negative…”
Get full text

Atezolizumab as the First Systemic Therapy Approved for Alveolar Soft Part Sarcoma by Bergsma, Emilie J., Elgawly, Mariam, Mancuso, David, Orr, Roger, Vuskovich, Theresa, Seligson, Nathan D.

“…Objective The objective was to review the pharmacology, efficacy, and safety of atezolizumab (Tecentriq) for the treatment of adult and pediatric patients aged…”
Get full text

Is weight-bearing as tolerated safe after proximal tibial metaphyseal autogenous bone harvest? A systematic review and meta-analysis by Sadr-Eshkevari, P., McGowan, C., Sekula, M., Sumner, R.K., Seligson, D., Flint, R.L.

“…Evidence was reviewed to assess the decrease in compressive strength postoperatively. The PRISMA guidelines were followed. PubMed, Embase, Web of Science,…”
Get full text

BRCA1/2 Functional Loss Defines a Targetable Subset in Leiomyosarcoma by Seligson, Nathan D., Kautto, Esko A., Passen, Edward N., Stets, Colin, Toland, Amanda E., Millis, Sherri Z., Meyer, Christian F., Hays, John L., Chen, James L.

“…Background Soft‐tissue sarcomas (STS) describe a heterogeneous group of mesenchymal tumors with limited treatment options. Targeted therapies exist for BRCA1/2…”
Get full text

PARP1 and POLD2 as prognostic biomarkers for multiple myeloma in autologous stem cell transplant by Thomas, Melissa, Li, Junan, King, Kevan, Persaud, Avinash K, Duah, Ernest, Vangundy, Zachary, Hofmeister, Craig C, Lamba, Jatinder K, Tan, Aik Choon, Fridley, Brooke L, Poi, Ming J, Seligson, Nathan D

“…Multiple Myeloma (MM) is an incurable plasma cell malignancy often treated by autologous stem cell transplant (ASCT). Clinical response to ASCT has been…”
Get full text

UGT1A1 Guided Cancer Therapy: Review of the Evidence and Considerations for Clinical Implementation by Nelson, Ryan S, Seligson, Nathan D, Bottiglieri, Sal, Carballido, Estrella, Cueto, Alex Del, Imanirad, Iman, Levine, Richard, Parker, Alexander S, Swain, Sandra M, Tillman, Emma M, Hicks, J Kevin

“…Multi-gene assays often include and, in certain instances, may report associated toxicity risks for irinotecan, belinostat, pazopanib, and nilotinib. However,…”
Get full text

P12 The preferred orientation for screw fixation of the calcaneal tuberosity by Gracey, S, Seligson, D

Get full text

Degree of MDM2 Amplification Affects Clinical Outcomes in Dedifferentiated Liposarcoma by Bill, Kate Lynn J., Seligson, Nathan D., Hays, John L., Awasthi, Achal, Demoret, Bryce, Stets, Colin W., Duggan, Megan C., Bupathi, Manojkumar, Brock, Guy N., Millis, Sherri Z., Shakya, Reena, Timmers, Cynthia D., Wakely, Paul E., Pollock, Raphael E., Chen, James L.

“…Background Dedifferentiated liposarcomas (DDLPS) are mesenchymal tumors associated with universally poor response to treatment. Genomic amplification of murine…”
Get full text

Clinical Utility of CDK4/6 Inhibitors in Sarcoma: Successes and Future Challenges by Hsu, Jocelyn Y, Seligson, Nathan D, Hays, John L, Miles, Wayne O, Chen, James L

“…Soft tissue and bone sarcomas are rare malignancies that exhibit significant pathologic and molecular heterogeneity. Deregulation of the…”
Get more information

CYP3A5 influences oral tacrolimus pharmacokinetics and timing of acute kidney injury following allogeneic hematopoietic stem cell transplantation by Seligson, Nathan D, Zhang, Xunjie, Zemanek, Mark C, Johnson, Jasmine A, VanGundy, Zachary, Wang, Danxin, Phelps, Mitch A, Roddy, Julianna, Hofmeister, Craig C, Li, Junan, Poi, Ming J

“…Polymorphisms in genes responsible for the metabolism and transport of tacrolimus have been demonstrated to influence clinical outcomes for patients following…”
Get full text

Gene partners of the EWSR1 fusion may represent molecularly distinct entities by Walker, Victoria, Jin, Dexter X., Millis, Sherri Z., Nasri, Elham, Corao-Uribe, Diana A., Tan, Aik Choon, Fridley, Brooke L., Chen, James L., Seligson, Nathan D.

“…•We identified 64 unique fusion partners. Rare fusion partners were identified more often in adults than children and included additional members of the ETS…”
Get full text

Inhibition of histone deacetylase 2 reduces MDM2 expression and reduces tumor growth in dedifferentiated liposarcoma by Seligson, Nathan D., Stets, Colin W., Demoret, Bryce W., Awasthi, Achal, Grosenbacher, Nicholas, Shakya, Reena, Hays, John L., Chen, James L.

“…Dedifferentiated liposarcoma (DDLPS) is a highly morbid mesenchymal tumor characterized and driven by genomic amplification of the MDM2 gene. Direct inhibition…”
Get full text

P09 The anterior intrapelvic approach to the acetabulum by MacKinlay, K, Houseman, B, Seligson, D

Get full text

OS1-05 Simultaneous nailing of the ipsilateral femur and tibia fractures: the up down nail by Auer, R, Seligson, D, Riehl, J

Get full text

Comparison of variants in TPMT and NUDT15 between sequencing and genotyping methods in a multistate pediatric institution by Cook, Kelsey J., Grusauskas, Victoria, Gloe, Lucy, Duong, Benjamin Q., Gresh, Renee C., Kolb, E. Anders, Bansal, Manisha, Bechtel, Allison S., Nagasubramanian, Ramamoorthy, Kirwin, Susan M., Blake, Kathryn V., Seligson, Nathan D.

“…The risk of severe adverse events related to thiopurine therapy can be reduced by personalizing dosing based on TPMT and NUDT15 genetic polymorphisms. However,…”
Get full text

A multicenter, randomized, non-comparative, phase II study of nivolumab ± ipilimumab for patients with metastatic sarcoma (Alliance A091401): expansion cohorts and correlative analyses by Seligson, Nathan D, Chen, James L, Goodrich, Austin C, Van Tine, Brian A, Campbell, Jordan D, Richards, Allison L, Antonescu, Cristina R, Liebner, David A, Milhem, Mohammed M, Streicher, Howard, Tap, William D, Schwartz, Gary K, George, Suzanne, D'Angelo, Sandra P

“…In this open-label, randomized, non-comparative, multicenter phase II study (Alliance A091401) we report on three expansion cohorts treated with nivolumab (N)…”
Get full text

Multiscale-omic assessment of EWSR1-NFATc2 fusion positive sarcomas identifies the mTOR pathway as a potential therapeutic target by Seligson, Nathan D., Maradiaga, Richard D., Stets, Colin M., Katzenstein, Howard M., Millis, Sherri Z., Rogers, Alan, Hays, John L., Chen, James L.

“…Sarcomas harboring EWSR1-NFATc2 fusions have historically been categorized and treated as Ewing sarcoma. Emerging evidence suggests unique molecular…”
Get full text

Drivers of genomic loss of heterozygosity in leiomyosarcoma are distinct from carcinomas by Seligson, Nathan D., Tang, Joy, Jin, Dexter X., Bennett, Monica P., Elvin, Julia A., Graim, Kiley, Hays, John L., Millis, Sherri Z., Miles, Wayne O., Chen, James L.

“…Leiomyosarcoma (LMS) is a rare, aggressive, mesenchymal tumor. Subsets of LMS have been identified to harbor genomic alterations associated with homologous…”
Get full text